Citadel Advisors’s Aptose Biosciences, Inc. APTO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-12,007
| Closed | -$38K | – | 15808 |
|
|
2025
Q1 | $38K | Buy |
+12,007
| New | +$58.4K | ﹤0.01% | 12591 |
|
|
2024
Q2 | – | Sell |
-856
| Closed | -$42.6K | – | 15879 |
|
|
2024
Q1 | $42.6K | Sell |
856
-1,207
| -59% | -$69.1K | ﹤0.01% | 12329 |
|
|
2023
Q4 | $155K | Buy |
2,063
+1,485
| +257% | +$115K | ﹤0.01% | 10330 |
|
|
2023
Q3 | $48.6K | Buy |
+578
| New | +$68.1K | ﹤0.01% | 11785 |
|
|
2023
Q2 | – | Sell |
-21
| Closed | -$5.92K | – | 15669 |
|
|
2023
Q1 | $5.92K | Sell |
21
-150
| -88% | -$43.6K | ﹤0.01% | 13838 |
|
|
2022
Q4 | $44.7K | Buy |
+171
| New | +$45.9K | ﹤0.01% | 12269 |
|
|
2022
Q3 | – | Sell |
-60
| Closed | -$20.7K | – | 14015 |
|
|
2022
Q2 | $20K | Buy |
60
+33
| +122% | +$15.8K | ﹤0.01% | 12416 |
|
|
2022
Q1 | $16K | Sell |
27
-225
| -89% | -$124K | ﹤0.01% | 13307 |
|
|
2021
Q4 | $153K | Sell |
252
-125
| -33% | -$117K | ﹤0.01% | 12229 |
|
|
2021
Q3 | $369K | Buy |
377
+166
| +79% | +$208K | ﹤0.01% | 10592 |
|
|
2021
Q2 | $316K | Buy |
211
+124
| +143% | +$270K | ﹤0.01% | 11134 |
|
|
2021
Q1 | $233K | Sell |
87
-120
| -58% | -$238K | ﹤0.01% | 11412 |
|
|
2020
Q4 | $409K | Sell |
207
-3,153
| -94% | -$7.41M | ﹤0.01% | 8520 |
|
|
2020
Q3 | $9.07M | Buy |
3,360
+2,964
| +748% | +$7.39M | ﹤0.01% | 2399 |
|
|
2020
Q2 | $1.12M | Sell |
396
-549
| -58% | -$1.77M | ﹤0.01% | 5621 |
|
|
2020
Q1 | $2.53M | Buy |
+945
| New | +$2.82M | ﹤0.01% | 3767 |
|
|
2019
Q4 | – | Sell |
-32
| Closed | -$41.7K | – | 9967 |
|
|
2019
Q3 | $30K | Buy |
+32
| New | +$36.4K | ﹤0.01% | 8849 |
|
|
2019
Q2 | – | Sell |
-73
| Closed | -$66K | – | 10066 |
|
|
2019
Q1 | $66K | Buy |
73
+32
| +78% | +$29K | ﹤0.01% | 8720 |
|
|
2018
Q4 | $35K | Sell |
41
-66
| -62% | -$64.9K | ﹤0.01% | 8578 |
|
|
2018
Q3 | $125K | Buy |
+107
| New | +$143K | ﹤0.01% | 8479 |
|
Other funds holding APTO
DS
GG
TWC
CSC
Citadel Advisors's APTO Position: Q2 2025 in Review
Citadel Advisors sold out of Aptose Biosciences, Inc. (APTO) in Q2 2025, closing a stake of 12,007 shares — an estimated $38K sold.
Citadel Advisors first reported a position in APTO in Q3 2018 and held it in 20 quarters. The position peaked at $9.07M in Q3 2020. 4 funds tracked by Wall St. Rank hold APTO as of Q2 2025.
- Citadel Advisors reported no remaining Aptose Biosciences, Inc. position as of Q2 2025 after selling out during the quarter.
- Citadel Advisors sold 12,007 Aptose Biosciences, Inc. shares in Q2 2025, an estimated $38K.
- Citadel Advisors first reported a position in Aptose Biosciences, Inc. in Q3 2018 and held it in 20 quarters.
- Citadel Advisors's Aptose Biosciences, Inc. position peaked at $9.07M in Q3 2020.
- 4 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2025.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.